thrombocytosis and circulating IL-6 levels), reduced endothelial cell dysfunction (reduced endothelial activation and circulating sVCAM), and a significant improvement in SCD-associated end-organ damage (nephropathy, pulmonary hypertension, pulmonary inflammation, liver function, inflammatory infiltration and micro-infarctions). Notably, all of these benefits were achieved with relatively modest 1.25-fold increase in prothrombin times, and in the absence of hemorrhagic complications. Taken together, these data establish that prothrombin is a powerful modifier of SCD-induced end-organ damage, and presents a novel therapeutic target to ameliorate SCD pathologies.
Introduction
Sickle cell disease (SCD) is a common monogenic disorder that affects millions worldwide and is caused by a mutant β -globin gene. It is characterized by erythrocyte sickling, chronic hemolytic anemia, episodic acute vaso-occlusions, chronic systemic inflammation at baseline, and acute and chronic cumulative organ damage. [1] [2] [3] [4] [5] [6] [7] Therapeutic options to prevent organ pathologies are limited to chronic transfusions, hydroxyurea or an allogeneic hematopoietic stem cell transplant (HCT). [8] [9] [10] [11] [12] A conspicuous feature of SCD is chronic activation of the coagulation system, often characterized by high levels of circulating D-dimer, thrombin-antithrombin (TAT) complexes, prothrombin fragment 1.2, increased tissue factor (TF) expression and high TF-bearing microparticles. 13, 14 Sickle cell-induced tissue damage is likely one driver of procoagulant activation, but sickle RBC membrane alterations and phosphatidylserine (PS) exposure may further augment procoagulant function. 15, 16 Thrombocytosis and platelet activation are also wellrecognized features of SCD. 4, 13, 14, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Thrombotic events including pulmonary embolism, deep vein thrombosis and SCD-related stroke are common. 17, [36] [37] [38] [39] [40] SCD-associated pulmonary hypertension (PHT) is associated with endothelial cell activation (as measured by soluble vascular cell adhesion molecule-1 [sVCAM-1]), which would also support procoagulant activity. 14, 20, 23, 41 However, the precise contribution of hemostatic factors to SCD-induced pathobiologies and particularly progressive end-organ damage has not been thoroughly explored.
A linkage between hemostatic system activation and inflammation is firmly established and this linkage was underscored in SCD by two recent studies in sickle mice. 42, 43 TF activity on endothelial cells was reported to support increased levels of IL-6 in SCD mice, and antibody blockade of TF activity suppressed circulating IL-6, sVCAM and pulmonary neutrophil infiltration. 42 Interestingly, rivaroxaban, a small molecule inhibitor of the prothrombin-activating protease, factor Xa (FXa) decreased IL-6, but not sVCAM; and dabigatran, a small molecule inhibitor of thrombin (FIIa), did not suppress either of these parameters. Thus, TF and FXa, but not FIIa, were linked to endothelial activation and/or inflammatory changes in SCD, and it was proposed that FIIa-independent signaling mechanism(s) mediated inflammatory effects in mice with SCD. 43 However, these fascinating studies were short-term in design, and did not explore the influence of hemostatic factors on the wide spectrum of multi-organ pathologies that manifest over long time frames in SCD. Furthermore, human studies exploring the role of the For personal use only. on January 12, 2018 . by guest www.bloodjournal.org From coagulation system activation employing anti-thrombotics in SCD patients have primarily focused either on reduction in acute sickle episodes and/or circulating markers of thrombin generation/inflammation as study endpoints [reviewed in 44 ] . The overall results from human studies show that while low-intensity anticoagulation diminished circulating markers of thrombin generation, effects on acute painful episodes were mixed, with either absent, modest, or significant reduction depending on the study. 44, 45 The central role of FIIa as a hemostatic protease is underscored by the fact that it controls fibrin deposition and stability (through fibrinogen, FXIII, and TAFI), regulates platelet and other cell signaling events (through PAR-1,-3 and -4) as well as positively and negatively mediating its own generation (through factors XI, VIII and protein C). FIIa also constitutes a key regulatory bridge between hemostasis/thrombosis, tissue repair, and inflammatory processes through multiple substrates, including fibrin, PARs, and other effectors. [46] [47] [48] [49] Urine albumin and osmolality. Twenty four-hour urine collections were used for determining albumin and creatinine, using ELISA kits from Bethyl Laboratories (Montgomery, TX), and R&D Systems (Minneapolis, MD) and osmolality, using a vapor pressure osmometer Vapro5600 (Wescor Biomedical Systems, South Logan, Utah).
Histopathology analysis. Mice were weighed before sacrifice. The heart was dissected to separate RV free wall, and LV+septum was weighed separately. All organs were fixed in 10% buffered formalin and embedded in paraffin. Sections (3-5 µm) were prepared for microscopic evaluation by a pathologist blinded to animal genotype following hematoxylin and eosin (H&E) and periodic acid Schiff's (PAS) staining. Lungs were inflation fixed with 4% paraformaldehyde solution in PBS.
Immunohistochemistry. Formalin-fixed, paraffin embedded sections of lung stained with anti α -SMA antibody (Sigma-Aldrich, St. Louis, MO) and secondary goat anti-mouse Alexa-Fluor-488 antibody were used for immunohistochemistry; 4',6'diamino-2-phenylindole.2HCL solution was added for nuclear staining, described in detail in supplemental material. Liver sections were stained for endothelial cells with rabbit anti-CD31 antibody (Abcam, Cambridge, MA) (1:50 dilution) followed by incubation with species-specific secondary antibodies and detected with UltraMax DAB kit (Ventana Laboratories,Tucson, AZ).
Cardiac Magnetic Resonance imaging (CMR).
CMR was performed as previously described.
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Statistical Analysis Data were analyzed using Graphpad Prism v6 (La Jolla, CA 
Results

FII Specific Antisense Oligonucleotide Decreases Early Mortality in Berkeley Sickle Mice.
As an initial approach, to explore the impact of prothrombin on SCD outcome, we tested the hypothesis that reducing FII levels improves SCD survival. Our Berkeley sickle mouse colony has a relatively high early mortality, with 40% SCD mice dying within 4-5 months (Supplemental Figure 1) . Cohorts of Berkeley sickle mice were injected with either a murine FII-specific or a control ASO-gapmer starting at 3 weeks of age for up to 15 weeks of age (Supplemental Figure 3A) . The FII-specific ASO-gapmer is complementary to the 3' noncoding portion of the F2 mRNA (a sequence found to be unique in the mouse genome), 52, 55 and specifically reduces hepatic F2 mRNA (thereby reducing circulating FII levels) without any impact on other coagulation system components (Supplemental Figure 2) . FII-specific ASO dose employed reduced circulating FII levels to approximately ~10% of normal ( Figure 1A ), a level of FII found here ( Figure 1B ) and previously 55, 56 to prolong prothrombin times mildly without causing spontaneous bleeding. More importantly, sickle mice treated with FII ASO showed significantly improved survival compared to sickle mice administered control ASO ( Figure 1C) . Indeed, the survival of Berkeley SCD mice treated with control ASO did not differ from the untreated Berkeley sickle mouse colony (Supplemental Figure 1) . These data show that low levels of FII exert a major survival advantage to sickle mice, conceivably reducing the general severity of SCD complications.
While this study was primarily designed to be a survival analysis, we attempted to analyze differences in the surviving mice, with the caveat that we were comparing "surviving fit" control-ASO mice with FII-ASO mice. The body weights were not significantly different between control-ASO or FII-ASO treated sickle mice (Supplemental Figure 3B) . Prothrombin times were modestly, but significantly (1.2-fold) higher in FII ASO mice compared to controls ( Figure 1B) .
D-dimer levels were reduced to 371 ± 48 ng/mL in FII ASO group as compared to 468 ± 69 in control ASO mice, although these differences were not statistically significant. TAT complexes, which are short-lived, and only reflect any proximal/short-term thrombin generated, as opposed to the sum of episodic thrombin generation over long-time frames (as likely in SCD) were not different in either group of sickle mice surviving at 15 weeks of age.
In addition, we attempted complementary studies using separate cohorts of sickle mice randomized at 3 weeks of age to FII-specific or control ASO, that were sacrificed at 9 weeks of For personal use only. on January 12, 2018. by guest www.bloodjournal.org From age, the mid time-point where significant early mortalities occur in sickle mice to assess differences in organ pathology (the experimental schema is shown in Supplementary Figure   4A ). All sickle mice exhibited some organ pathology. However, at this early age, no major pathological differences in kidney, lung, liver, heart and other tissues other than vascular congestion were seen between control and FII ASO mice (Supplemental Figure 4B) , suggesting that the survival benefits conferred by FII ASO gapmer in young SCD mice may be due to the evasion of an acute sickle event rather than cumulative end-organ damage. While the precise cause(s) of death in very young sickle cell mice was not obvious based on histological tissue surveys, and remains to be formally established, reduced prothrombin presented a clear benefit in life expectancy.
Genetically Imposed Reduction in FII levels in SCD Mice Reduces Thrombin Generation.
To gain better functional insight into the long-term advantages of diminished FII levels in sickle mice, and to do so without potential animal stress or challenges associated with weekly ASO gapmer administration, we employed a FII germline mutation approach. Here, using HCT, we generated sickle hematopoietic chimeras on Figure 7) . TAT levels in non-transplanted Berkeley sickle mice also showed similar patterns, with some mice showing high TAT levels and others not, and were also not significantly different compared to
Berkeley HbA animals (data not shown).
Reduction in FII Levels in SCD Decreases Inflammation and Endothelial Cell Dysfunction.
As animals, although monocyte numbers were lower in HbA/FII lox/-mice. There was no significant difference in the lymphocyte count between these animals (Supplemental Figure 8 ).
This diminution of leukocytosis FII in HbS/FII lox/-animals was also accompanied by significantly reduced IL-6, a systemic marker of inflammation, and reduced levels of the endothelial cell activation marker sVCAM, as compared to HbS/FII WT mice (Figure 3E-F) . These markers of inflammation and endothelial dysfunction were at low levels in HbA/FII WT mice and remained unchanged in HbA/FII lox/-animals.
Reduction in FII Levels in SCD Protects Against Sickle Nephropathy.
To assess the impact of lowered FII on the cumulative organ damage associated with SCD, we examined its effect on sickle nephropathy, a serious complication that results in progressive albuminuria in 50-70% of adults and renal failure and mortality in approximately 30% of SCD patients. Consistent with the improved histology, HbS/FII lox/-mice showed a highly significant decrease in albuminuria. Although hyposthenuria was also significantly improved, this difference was not as pronounced as the improvement in albuminuria. These results indicate that procoagulant function significantly contributes to the renal, and specifically the glomerular pathology in SCD, and lowering FII in mice with SCD protects against development of sickle nephropathy.
Reduction in FII results in Improved SCD-Associated Cardiopulmonary Pathologies.
Pulmonary hypertension (PHT) and ventricular diastolic dysfunction are recognized complications of SCD and have been shown to be associated with coagulation activation, endothelial dysfunction, and inflammation. 14, 34 While the incidence of right heart catheterization proven PHT in SCD adults is now estimated at 6-10%, 60 mice. The latter is a feature of airway reactivity, another known association with SCD. [65] [66] [67] As anticipated PHT and other associated pulmonary pathologies were absent in HbA chimeras.
Additionally, lung histology revealed presence of foamy alveolar macrophages, thickened arterial/arteriolar tunica media, and increased lymphocyte and macrophage infiltration ( Figure   6A-C) . Edema around the blood vessels and vascular congestion was also pronounced in HbS/FII WT mice. In contrast, all of these pathologies were remarkably reduced in HbS/FII lox/-mice ( Figure 6A-C) . These changes were absent in both the HbA chimeric controls (Supplemental Figure 11) .
Together, these data indicate that increased thrombin generation contributes to the cardiopulmonary pathologies in SCD; and consistent with a decrease in circulatory markers of inflammation, pulmonary inflammation is also reduced with diminution of circulating FII. (Figure 7F-H) . Consistent with the diminished microscopic evidence of hepatic damage, plasma alanine transaminase activity was also significantly lower in HbS/FII lox/-mice compared to HbS/FII WT mice ( Figure 7E) . No hepatic histopathological changes or elevation in transaminase activity was observed in HbA chimeras, regardless of FII levels ( Figure 7E; Supplemental Figure 12 ).
Reduced FII Levels Protect
Discussion
In this study we show that FII plays a significant role in inflammation and multi-organ pathologies in mice with SCD. Consistent with prior work, 50 we found that even in SCD mice, reducing the circulating FII to 10% of normal was associated with a relatively mild prolongation in the PT and reduced markers of FIIa activity, but was not associated with spontaneous bleeding. Moreover, these mild increases in PT are well below clinical PT targets for safe and effective anticoagulation. Yet, there was an impressive reduction in inflammation or associated reactive changes: there was significantly diminished (i) leukocytosis, specifically neutrophilia and monocytosis, (ii) circulating IL-6, (iii) inflammatory infiltrates in lung, liver and kidneys, (iv) vascular dysfunction (sVCAM) and (v) thrombocytosis. In addition, there was marked improvement in cardiac, renal, pulmonary and hepatic histology and function: amelioration of RV hypertrophy and dilatation, albuminuria and hyposthenuria. Of note, this reduction in inflammation and organ pathologies was not due to a change in the RBC parameters, suggesting no correlation of the inflammation with the underlying chronic hemolytic anemia or RBC turnover (reticulocytosis) with reduced circulating FII. These findings also suggest that reduction in FII is unlikely to limit hemolysis and free hemin-induced events, such as TLR-4 activation, 68 although this has not been formally excluded. Rather, diminution of FII likely limited the vaso-occlusive manifestations of SCD and the secondary inflammation. An ultimate entirely objective indicator of the benefit of this intervention was the significantly improved survival of Berkeley sickle mice carrying low levels of FII.
A connection between sickle RBC, the hemostatic system and SCD pathobiology has been long-speculated. Vaso-occlusions are the hallmark of SCD, and thrombotic changes secondary
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From to sickling-induced vascular damage and sludging of blood flow are also innate to its pathophysiology. Consequently, the potential significance of procoagulant function in SCD has been recognized for decades. Prior studies of the anticoagulant vitamin K antagonist (VKA), warfarin, given during acute vaso-occlusive events (VOE) suggested no effect on the duration of VOE in the short-term, 69 and showed a modest reduction in VOE (from 1.3 VOE/year to 0.9 VOE/year) when given long-term. However the authors acknowledged that the anticoagulation was poorly controlled and therefore, the intervention had associated bleeding episodes in some patients. 69 VKAs have the disadvantage of lowering all vitamin K-dependent factors, including the anti-coagulant and anti-inflammatory protein C. Thus, based on these early findings, the benefits, of targeting the coagulation system, in general, remained uncertain, and any long-term benefits and liabilities of interventions at the level of a selected procoagulant have remained entirely unknown.
The present study unambiguously establishes, for the first time, that intervention at the level of a single key hemostatic factor, FII, can significantly ameliorate SCD organ pathologies and improve survival, at least in mice. FII-specific ASO provides complementary proof-of-principle of the potential utility of pharmacological intervention. A recent high-profile clinical trial using a FXIspecific ASO gapmer established their utility in safely attenuating postoperative venous thromboembolism. 70 While first-generation ASOs have been associated with proinflammatory effects, 71 second-generation ASO gapmers are devoid of these side effects due to their advanced chemistries, high sequence specificity and comprehensive screening strategies. 72 Based on the present findings, it will be of keen interest to now also explore long-term benefits of interventions of this type or direct thrombin or FXa inhibitors in future studies of SCD. While FII-specific ASO gapmers may have potential short-term utility in venous thromboembolism, their long-term use for the prevention of chronic organ damage in SCD may have compliance issues. In this regard, recent studies of SCD in mice intervening at the level of tissue factor (TF), the premiere initiator of the coagulation system, suggested suppressing TF activity reduced endothelial cell activation markers (sVCAM) and inflammatory markers (IL-6). 42 Yet no such benefits were reported with regard to either of these metrics in mice treated with the oral FIIa inhibitor, dabigatran in the short duration of 10 days. 43 Our report demonstrates that intervention at the level of FII in sickle mice can mirror findings made previously with TF blocking antibodies in reducing circulating sVCAM and IL-6. However, the seeming discrepancy with prior dabigatran studies could simply reflect the distinct experimental observation periods (young adults studied for 10 days vs. mice studied for 10-12 months) and the known progressive nature Recent studies have examined the components of the coagulation system in human subjects and in mouse models of SCD. 44 Increased TF expression secondary to sickling and SCDinduced vascular endothelial/tissue damage is one likely driver of procoagulant activation.
Recent evidence suggests that besides coagulation system activation from vascular endothelial/tissue damage, sickle RBC membrane damage and PS exposure (plus PS-positive RBC microparticles) may be a significant driver of chronic thrombin generation and coagulation system activation, especially given their exceptional mass and turnover in SCD. 34, 73 Lowering FII in mice with SCD would be anticipated to limit the chronic procoagulant response to diminish both vaso-occlusion and inflammation. In addition to this, benefits of thrombin suppression could be gained at the level of both reduced platelet activation and reduced reactive changes leading to thrombocytosis. 26 Although we did not examine platelet activation, our data suggests that part of the thrombocytosis in the HbS/FII lox/-mice was reactive, secondary to the chronic inflammation that results from increased thrombin generation. . 74 The availability of Fibγ 390-396A mice carrying a mutant form of fibrinogen lacking the primary α M β 2 binding motif, but supporting clotting function, provide an attractive means for testing the concept that this thrombin target is coupled to SCD pathophysiology without imposing a hemorrhagic risk. 75 The viability of mice lacking other thrombin substrates, such the fibrin-stabilizing transglutaminase FXIII, provides an opportunity for more detailed mechanistic studies. If indeed dampening the proinflammatory effect of fibrin(ogen) offers benefit in SCD, the wholesale absence of clotting function is likely to be distinctly counterproductive, as the complete absence of fibrin(ogen) in an established, albeit far milder, model of SCD (transgenic SAD mice) resulted in increased mortality. 76 A second, and not mutually exclusive target of FIIa that may be mechanistically coupled to SCD outcome is protease activated receptor-1 (PAR-1). Proteolytic activation of PAR-1 on endothelial cells results in a spectrum of functional changes that could be linked to SCD pathobiology, including changes in adhesive properties, the elaboration of hemostatic proteins, and changes in vascular
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From permeability. While short-term studies in PAR-1-deficient mice with SCD did not show significant benefits, 43 longer term studies may be needed to better define any PAR-1 and/or PAR-4 involvement.
Increased TF expression in monocytes and endothelium and monocyte-TF bearing microparticles have been reported in patients with SCD 13, 25 and been associated with SCD pathologies including increased peak pulmonary artery pressures; however, the reports have been controversial, with some studies showing an association and others not. 14, [77] [78] [79] Studies on mouse models of SCD lend credence to the clinical associations while also illuminating causality. Here, we show that a genetically-imposed chronic deficit in prothrombin, leading to a relatively modest increase in PT is a major modifier of inflammation and organ pathology in SCD mice. A prothrombotic state is known to predispose to pulmonary microemboli and pulmonary vascular pruning in non-SCD associated PHT. 80 We show that this also occurs in SCD, where reduction in procoagulant function prevents development of PHT. In addition, we show a pleiotropic amelioration of multi-organ dysfunction. Of note, the remarkable improvement in glomerulopathy (reduction in albuminuria and FSGS), lung and liver pathology implies that this is a primarily microvascular effect, since these tissues are rich in capillaries. Reduced thrombinmediated endothelial cell activation, as evidenced by plasma sVCAM levels (and thereby reduced RBC and WBC endothelial cell adhesion) and leukocytosis in HbS/FII lox/-mice likely reduces microvascular blockade, as was observed in liver sections. While Gavin et al have
shown that direct inhibition of thrombin acutely via antithrombin III or hirudin reversed the accelerated experimentally induced thrombus formation in large vessels subjected to light/dye injury induced cerebral thrombosis in sickle mice, 17 we show that chronic reduction in FIIa also limits microvascular thrombosis and endothelial dysfunction, impeding chronic end-organ damage. Its effect on stroke prevention, however, could not be elucidated, as SCD mouse model is not a good model of unprovoked stroke. Overall, our studies establish that prothrombin diminution imparts substantial long-term benefit to multiple organs in SCD mice under normoxic day to day conditions, likely from reduced vascular occlusions, at least in the liver. It will be of added interest to explore whether short-term benefits are also gained in SCD mice when subjected to hypoxia 4 or other secondary challenges (e.g., TNFα). 81 Several human trials with anticoagulants 45, 82 and antiplatelet agents [83] [84] [85] [86] [87] [88] [89] have been conducted, but have mostly been non-randomized non-placebo controlled studies in small cohorts of patients. These studies have been limited by complex endpoints such as SCD-associated pain,
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which have thus far yielded mixed results. Nevertheless, these studies have shown that some of the anticoagulant and antiplatelet agents can be safely given to patients with SCD without inordinate risk of bleeding. 45, [82] [83] [84] [85] [86] [87] [88] [89] Two placebo controlled studies of acencoumarol and tinzaparin have been performed, 90, 91 of which the large randomized placebo-controlled trial by Qari et al has shown a significant effect of tinzaparin, a low molecular weight heparin, in reducing VOE. weeks) with equal numbers of males and females distributed among the experimental groups.
Fully chimeric sickle or normal mice were followed for a year after transplantation. 
